Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- UT Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
AMED 
Amedisys Inc (AMED)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/31/2024: AMED (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -22.17% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/31/2024 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.97B USD | Price to earnings Ratio 36.03 | 1Y Target Price 96.86 |
Price to earnings Ratio 36.03 | 1Y Target Price 96.86 | ||
Volume (30-day avg) 631082 | Beta 0.78 | 52 Weeks Range 82.15 - 98.95 | Updated Date 12/31/2024 |
52 Weeks Range 82.15 - 98.95 | Updated Date 12/31/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.52 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.57% | Operating Margin (TTM) 8% |
Management Effectiveness
Return on Assets (TTM) 6.27% | Return on Equity (TTM) 7.21% |
Valuation
Trailing PE 36.03 | Forward PE 18.08 | Enterprise Value 3186171356 | Price to Sales(TTM) 1.28 |
Enterprise Value 3186171356 | Price to Sales(TTM) 1.28 | ||
Enterprise Value to Revenue 1.37 | Enterprise Value to EBITDA 14.09 | Shares Outstanding 32754500 | Shares Floating 32099711 |
Shares Outstanding 32754500 | Shares Floating 32099711 | ||
Percent Insiders 1.87 | Percent Institutions 90.29 |
AI Summary
Amedisys Inc. Stock Overview
Company Profile:
History and Background:
Amedisys Inc. (NASDAQ: AMED) is a leading national home health, hospice, and personal care services provider founded in 1982. The company started as a small home health agency in Baton Rouge, Louisiana, and has grown through acquisitions and organic expansion to become one of the largest home health providers in the United States.
Core Business Areas:
- Home Health: Amedisys provides skilled nursing, physical therapy, occupational therapy, and speech therapy to patients in their homes.
- Hospice: Amedisys provides end-of-life care to patients with a terminal illness.
- Personal Care: Amedisys provides non-medical assistance with activities of daily living, such as bathing, dressing, and eating.
Leadership and Corporate Structure:
Amedisys is led by Paul Kusserow, President & CEO, and Christopher Gerard, CFO. The company operates through a decentralized structure with regional offices and home health, hospice, and personal care agencies across the United States.
Top Products and Market Share:
Top Products:
- Home Health Services
- Hospice Services
- Personal Care Services
Market Share:
- Amedisys is the third-largest home health provider in the United States with a market share of approximately 6%.
- The company is also a leading provider of hospice and personal care services.
Product Performance and Market Reception:
- Amedisys has a strong track record of providing high-quality care to patients. The company has received numerous awards and accolades, including recognition from the National Committee for Quality Assurance (NCQA) and the Joint Commission.
- Amedisys is also well-positioned to benefit from the growing demand for home-based care services due to the aging population and the increasing prevalence of chronic diseases.
Total Addressable Market:
The total addressable market for home health, hospice, and personal care services in the United States is estimated to be over $200 billion.
Financial Performance:
Recent Financial Performance:
- Revenue: $2.9 billion in 2022
- Net Income: $140 million in 2022
- Profit Margin: 4.9% in 2022
- Earnings per Share (EPS): $0.80 in 2022
Year-over-Year Comparison:
- Revenue increased by 12% in 2022 compared to 2021.
- Net income increased by 18% in 2022 compared to 2021.
- EPS increased by 19% in 2022 compared to 2021.
Cash Flow and Balance Sheet Health:
- Amedisys has a strong cash flow position with $150 million in cash and equivalents as of December 31, 2022.
- The company also has a healthy balance sheet with a debt-to-equity ratio of 0.7.
Dividends and Shareholder Returns:
Dividend History:
- Amedisys has a history of paying dividends to shareholders.
- The company's current dividend yield is 1.5%.
- The company's payout ratio is 20%.
Shareholder Returns:
- Amedisys' stock has returned 10% over the past year.
- The company's stock has returned 50% over the past five years.
Growth Trajectory:
Historical Growth:
- Amedisys has grown revenue at a compound annual growth rate (CAGR) of 10% over the past five years.
- The company has grown earnings per share (EPS) at a CAGR of 15% over the past five years.
Future Growth Projections:
- Amedisys is expected to grow revenue at a CAGR of 5% over the next five years.
- The company is expected to grow earnings per share (EPS) at a CAGR of 10% over the next five years.
Market Dynamics:
Industry Overview:
- The home health, hospice, and personal care services industry is expected to grow at a CAGR of 8% over the next five years.
- The industry is being driven by the aging population, the increasing prevalence of chronic diseases, and the shift towards home-based care.
Amedisys' Positioning:
- Amedisys is well-positioned to benefit from the growth of the home health, hospice, and personal care services industry due to its national footprint, strong brand recognition, and high-quality care services.
Competitors:
- Key competitors of Amedisys include:
- LHC Group (LHCG)
- Option Care Health (OPCH)
- Addus HomeCare Corporation (ADUS)
- Almost Family (AFAM)
- Amedisys has a competitive advantage over its competitors due to its size, scale, and national presence.
Potential Challenges and Opportunities:
Challenges:
- Amedisys faces challenges such as reimbursement cuts, labor shortages, and competition.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Baton Rouge, LA, United States | ||
IPO Launch date 1994-08-17 | President, CEO & Director Mr. Richard M. Ashworth | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 19000 | Website https://www.amedisys.com |
Full time employees 19000 | Website https://www.amedisys.com | ||
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.